Clinical Pharmacology in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: closed (31 January 2025) | Viewed by 2697
Special Issue Editor
Interests: pharmacology of anti-cancer therapies; personalized medicine in cancer; colorectal cancer development, progression, and therapies; epigenetics and gene regulation; preclinical models; drug toxicity
Special Issue Information
Dear Colleagues,
Cancer therapeutic options are rapidly evolving and include the development of new advanced therapies that target vulnerabilities specific to cancer cells and the optimization of existing therapies to increase the efficacy and/or reduce occurrence of treatment-related adverse events. It is an exciting time for cancer pharmacology, with rapid advances improving treatment options for many cancer types at an unprecedented pace.
The purpose of this Special Issue is to highlight cutting-edge research in cancer pharmacology, including (1) the identification of new therapeutic targets in cancer and/or the development of new or refined targeted therapeutics, (2) improved methods for individualized anti-cancer therapies based on novel predictive biomarkers of the therapeutic response or toxicity, and (3) therapeutic resistance mechanisms and means to overcome resistance. Original research articles using preclinical or clinical models, as well as comprehensive reviews, are welcome for this Special Issue.
Dr. Steven Offer
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacology
- personalized medicine
- pharmacogenomics/pharmacogenetics
- cancer
- chemotherapy
- targeted therapy
- clinical trials
- preclinical models
- therapeutic toxicity
- therapeutic efficacy
- therapeutic resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
